Ketamine enantiomers in the rapid and sustained antidepressant effects
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Recent evidence has suggested that the N-methyl-D-aspartate receptor antagonist ketamine shows significant therapeutic effects in major depression and bipolar disorder. This effect is especially important in treatment-resistant depression and depression with suicidal ideation. In this review we explain the mechanism of action, drug efficacy, and the side effects of ketamine; the antidepressive effects of ketamine; the individual effects of ketamine isomers, R(–) ketamine and S(+) ketamine; the effects of the combination of ketamine with electroconvulsive therapy; and the possible use of ketamine in treating depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As mentioned previously in this review, there appear to be differences in the degree of adverse effects between the enantiomers of ketamine, although the two enantiomers have not yet been compared in a comprehensive head-to-head clinical study.27,34”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The S-enantiomer of ketamine (esketamine) is a more potent antagonist than R-ketamine at the phencyclidine site on the glutamate NMDA receptor,27–31 and has stronger analgesic potency than either R-ketamine or racemic ketamine.32”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“The S-enantiomer of ketamine (esketamine) is a more potent antagonist than R-ketamine at the phencyclidine site on the glutamate NMDA receptor,27–31 and has stronger analgesic potency than either R-ketamine or racemic ketamine.32”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 6×
“Furthermore, it is important to note that other antidepressants do not stimulate mTOR [Li et al. 2010].”
BackgroundInfluentialNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
McEwen, B. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.071 · Cited by 1,864
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“S ketamine has about a fourfold greater affinity for the NMDA receptor and greater anesthetic potency http://tpp.sagepub.com 189 [Domino, 2010].”
BackgroundR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Research works printed but not linked: 3
- Rasmussen K., 1996, Convuls Ther, 12, 217
- 10.1002/1098-1063(2000)10:4<411::AID-HIPO7>3.0.CO;2-A · doi:10.1002/1098-1063(2000)10:4<411::aid-hipo7>3.0.co;2-a
- Vuyk J., 2015, Miller’s Anesthesia, 821
Cited by
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Coelho, M. M., Fernandes, C., Remião, F., & Tiritan, M. E. (2021) · Molecules · doi:10.3390/molecules26113113 · Cited by 159
Esketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
“There is considerable disagreement in the literature about the degree of adverse effects such as dissociation, psychoses, and cognitive effects with esketamine [29–45]and readers are referred especially to two comprehensive review articles on this matter [30,40]; it should be remembered that some of the studies report…”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 124
The Neuropsychology of Anxiety: An enquiry into the functions of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · doi:10.1093/oso/9780198843313.001.0001 · Cited by 97
Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000179 · Cited by 91
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Esketamine: A Novel Option for Treatment-Resistant Depression
Bozymski, K. M., Crouse, E. L., Titus-Lay, E. N., Ott, C. A., Nofziger, J. L., & Kirkwood, C. K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019892644 · Cited by 82
Ma, J., Wang, F., Wang, J., Wang, P., Dou, X., Yao, S., & Lin, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s406568 · Cited by 80
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Wen, Y., Xu, J., Shen, J., Tang, Z., Li, S., Zhang, Q., Li, J., & Sun, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-023-03860-4 · Cited by 79
Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62
Glutamatergic systems in neuropathic pain and emerging non-opioid therapies
Temmermand, R., Barrett, J. E., & Fontana, A. C. K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106492 · Cited by 70
Kim, S. W., Rush, B. S., & Rice, T. (2020) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01542-3 · Cited by 65
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 56
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 47
Engaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 46
Passie, T., Adams, H.-A., Logemann, F., Brandt, S. D., Wiese, B., & Karst, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.005 · Cited by 48
Chiral carbon nanostructures: a gateway to promising chiral materials
Niu, X., Liu, Y., Zhao, R., Wang, L., Yuan, M., Zhao, H., Li, H., Yang, X., & Wang, K. (2024) · Journal of Materials Chemistry A · doi:10.1039/d4ta02396j · Cited by 38
Ketamine and Calcium Signaling—A Crosstalk for Neuronal Physiology and Pathology
Lisek, M., Żylińska, L., & Boczek, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218410 · Cited by 44
Lucchese, A. C., Sarin, L. M., Magalhães, E. T. P., Sant, L. C. D., Puertas, C. B., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120978398 · Cited by 39
Ketamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings
Silote, G. P., de Oliveira, S. F. S., Ribeiro, D. E., Machado, M. S., Andreatini, R., Joca, S. R. L., & Beijamini, V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109878 · Cited by 35
Rothärmel, M., Benosman, C., El‐Hage, W., Berjamin, C., Ribayrol, D., Guillin, O., Gaillard, R., Berkovitch, L., & Moulier, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.865466 · Cited by 39
Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review
Song, B., & Zhu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.782457 · Cited by 32
Urothelial toxicity of esketamine in the treatment of depression
Findeis, H., Sauer, C., Cleare, A. J., Bauer, M., & Ritter, P. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05611-y · Cited by 29
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 34
Ren, Y.-L., Yuan, J., Xing, F., Zhu, L.-N., & Zhang, W. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00488-z · Cited by 31
Zhu, J., Hawkins, E., Phillips, K. F., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 29
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 28
Jeon, H. J., Ju, P., Sulaiman, A. H., Aziz, S. A., Paik, J., Tan, W., Bai, D., & Li, C. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.70 · Cited by 27
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
Sant, L. C. D., Sarin, L. M., Magalhães, E. T. P., Lucchese, A. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., Steglich, M. S., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120922955 · Cited by 26
Zhang, J., Wang, F., Dang, J., Zheng, H., Ren, B., Liu, C., Zuo, R., Wang, R., Liu, T., & Wang, Z. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00519-9 · Cited by 29
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
Smith-Apeldoorn, S. Y., Vischjager, M., Veraart, J. K. E., Kamphuis, J., Rot, M. A. H., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084055 · Cited by 29
Lipsitz, O., McIntyre, R. S., Rodrigues, N. B., Kaster, T. S., Cha, D. S., Brietzke, E. M., Gill, H., Nasri, F., Lin, K., Subramaniapillai, M., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 31
Sartim, A. G., Marques, J., Silveira, K. M., Gobira, P. H., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108679 · Cited by 27
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 20
Role of Ketamine in the Treatment of Psychiatric Disorders
Derakhshanian, S., Zhou, M., Rath, A., Barlow, R., Bertrand, S. C., DeGraw, C., Lee, C., Hasoon, J. J., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25091 · Cited by 27
Phillips, A. G., Geyer, M. A., & Robbins, T. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.014 · Cited by 22
Hirota, K., & Lambert, D. G. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.08.020 · Cited by 20
Barbosa, M. G., Delfino, R. S., Sarin, L. M., & Jackowski, A. P. (2020) · Palliative Medicine · doi:10.1177/0269216320910351 · Cited by 18
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
Qu, H., Wang, F., Barrett, H., Wang, B., Han, J., Wu, J., Huang, X., Hu, Y., & Yu, G. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113415 · Cited by 17
New Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 17
Fernandes, M., Schelotto, M., Doldi, P. M., Milani, G., Manzano, A. A. A., Valdivia, D. P., Winter-Matos, A., Abdelrahim, Y. H., Bek, S. A. H., Benitez, B. K., et al. (2021) · F1000Research · doi:10.12688/f1000research.27809.1 · Cited by 14
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Feifel, D. (2016) · Drug Development Research · doi:10.1002/ddr.21347 · Cited by 17
Sun, L., Zhao, Y., Yan, L., Zhai, W., Gao, F., Yin, Q., Cheng, W., Wang, Z., & Zeng, Y. (2023) · PubMed Central · Cited by 23
Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats
Štefková, K., Danda, H., Dehaen, W., Jurásek, B., Šíchová, K., Pinterová, N., Mazoch, V., Krausová, B. H., Kysilov, B., Smejkalová, T., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15680 · Cited by 15
Li, C., Shi, J., Wei, S., & Jia, H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01511-x · Cited by 10
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia
Maraschin, J. C., Frias, A. T., Hernandes, P. M., Batistela, M. F., Martinez, L. M., Joca, S. R. L., Graeff, F. G., Audi, E. A., de Andrade, T. G. C. S., & Zangrossi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113651 · Cited by 8
Barbosa, M. G., Garcia, G. T., Sarin, L. M., & Jackowski, A. P. (2022) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2876 · Cited by 16
Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression
Liu, G.-L., Cui, Y., Lu, C., & Zhao, P. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109006 · Cited by 12
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 8
Harvey, A. J., Nikolin, S., Chand, N., Flanney, W., Tan, L., Moffa, A. H., Loo, C. K. A., & Martin, D. M. (2023) · Depression and Anxiety · doi:10.1155/2023/3371272 · Cited by 8
Shadli, S. M., Delany, R. G., Glue, P., & McNaughton, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.900105 · Cited by 5
Barrutieta-Arberas, I., Ortuzar, N., Vaquero-Rodríguez, A., Picó-Gallardo, M., Bengoetxea, H., Guevara, M., Gargiulo, P. A., & Lafuente, J. V. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231170007 · Cited by 6
Unmet Needs in Psychiatry: Bipolar Depression
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_4 · Cited by 8
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
On the Chirality of Drugs and the Structures of Biomacromolecules
Belova, E., Semenova, E. V., & Tverdislov, V. A. (2022) · BIOPHYSICS · doi:10.1134/s0006350922030034 · Cited by 4
Ketamine: An emerging agent in the management of neuropsychiatric disorders
Menke, N. B., Hoffman, E., Gaylor, K., & Shobassy, A. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104351 · Cited by 4
Antidepressant Actions of Ketamine and Its Two Enantiomers
Chang, L., Wei, Y., & Hashimoto, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_7 · Cited by 4
Ketamine Treatment for Mood Disorders
Klise, A., Lerner, B. S., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180315-01 · Cited by 2
Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections
Barbosa, M. G., Sarin, L. M., Tuena, M. A., Sant, L. C. D., Nakahira, C., Magalhães, E. T. P., Fava, V. A. R., Delfino, R. S., Steglich, M. S., Puertas, C. B., et al. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100053 · Cited by 3
Terapia antidepresiboaren azken pausoak: oraina eta geroa
Erkizia-Santamaría, I., Ortega, J. E., & Horrillo, I. (2020) · Osagaiz osasun-zientzien aldizkaria · doi:10.26876/osagaiz.2.2020.311 · Cited by 2
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0012 · Cited by 2
Zhang, K. Y., Bao, Y., Wang, M., Yang, Y., Zhai, W., & Gao, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1697135/v1 · Cited by 2
The use of lidocaine and ketamine in the setting of abdominal surgery
Ostović, H., Šimac, B., & Peršec, J. (2022) · Liječnički vjesnik · doi:10.26800/lv-144-supl3-8 · Cited by 1
A Pain Physician and Anesthesiologist’s Perspective on Ketamine for Treatment-Resistant Depression
Gatewood, L. E., Gorlin, A. W., Bailey, C. H., Barsoum, G., & Porter, S. B. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01439-7 · Cited by 1
Simulation of nanocarrier-based targeted delivery of an antidepressant for major depressive disorder
Mehra, V., Sarkar, N., Biswal, B., & Kaushik, M. (2023) · Molecular Simulation · doi:10.1080/08927022.2023.2241764 · Cited by 2
Lee, J., Jeon, S., Kim, N., Choi, S.-M., Do, W., Kim, J.-R., Kim, E., Hong, J.-M., & Baik, J. (2023) · Medical Science Monitor · doi:10.12659/msm.942574 · Cited by 2
Fundamentals of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0009 · Cited by 1
Memory and the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0008 · Cited by 1
An update of systemic analgesics in children
Smith, K. P., & Chauhan, A. (2025) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2024.12.006 · Cited by 1
Racemic Ketamine and Esketamine for Treatment of Refractory and Super-Refractory Status Epilepticus
ElSayed, M., Latifi, K., Abdelwahab, L., Mourid, M. R., Kandil, H. S., Khan, D. I., & Shehata, I. M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_9 · Cited by 2
Salter, M. D., & Gunja, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818788-3.00011-5 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
Roncalho, A. L. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2022.tde-12072022-152441 · Cited by 1
Utilisation de la kétamine en psychiatrie : mise à jour
Clerc, M.-T., Rosenhagen-Lapoirie, M., & von Gunten, A. (2022) · JMIG · doi:10.53738/revmed.2022.18.793.1626
What do hippocampal cell fields represent?
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0007
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0001 · Cited by 1
The neurology of anxiety—planning circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0011
A theory of the septo-hippocampal system (SHS)
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0010
Symptoms and syndromes of anxiety
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0013
The neurology of anxiety—survival circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0006
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0002
Metadata
- Authors
- Muller, J., Pentyala, S., Dilger, J., & Pentyala, S.
- Affiliations
- Stony Brook University Hospital (US)
- Corresponding author
- Pentyala, Srinivas
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-10
- Volume
- 6
- Issue
- 3
- Pages
- 185-192
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910398
- OpenAlex
- W2320782138
- Cited by
- 122
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 30 · 2023: 14 · 2022: 17 · 2021: 18 · 2020: 19 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 1
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, ketamine enantiomers, (R)-ketamine, esketamine, antidepressant effects, major depressive disorder, bipolar disorder, treatment-resistant depression, suicidal ideation, NMDA receptor antagonists, mechanism of action, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.